Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
<p>A-C. FFPE sections of PC were stained by multiplex staining panel for CD4, CD8, FoxP3 (T regulatory cells), CD19 (B cells), CD68 (macrophages). Stained sections were imaged on the Hamamatsu slide scanner NanoZoomer S360 and images were viewed on the NDP viewer software. Analysis of images w...
में बचाया:
| मुख्य लेखक: | |
|---|---|
| अन्य लेखक: | , , , , , , , , , , , , |
| प्रकाशित: |
2025
|
| विषय: | |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
| _version_ | 1849927634557861888 |
|---|---|
| author | Ulka N. Vaishampayan (15051039) |
| author2 | Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ulka N. Vaishampayan (15051039) Archana Thakur (15051042) Wei Chen (15051045) Abhinav Deol (15051048) Meera Patel (15051051) Kimberlee Dobson (15051054) Brenda Dickow (15051057) Dana Schalk (15051060) Amy Schienschang (15051063) Sarah Whitaker (15051066) Amanda Polend (15051069) Joseph A. Fontana (411960) Elisabeth I. Heath (15024674) Lawrence G. Lum (15051072) |
| dc.date.none.fl_str_mv | 2025-11-25T12:41:18Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30705749 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_S3_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705749 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| dc.title.none.fl_str_mv | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>A-C. FFPE sections of PC were stained by multiplex staining panel for CD4, CD8, FoxP3 (T regulatory cells), CD19 (B cells), CD68 (macrophages). Stained sections were imaged on the Hamamatsu slide scanner NanoZoomer S360 and images were viewed on the NDP viewer software. Analysis of images were performed on online Visiopharm software. Using the low power image, high-powered Fields (HPFs) were selected from specific tumor regions. Data shows the distribution of CD4+ (teal), CD8+ (purple), FoxP3 (brown), CD19+ (green) and CD68+ (yellow) cells on two representative whole scanned slide images (KCI 04 and KCI 11) are shown. Top panel shows whole scanned tumor sections, inset 1 and 2 are shown below at high magnification (40x). B and C) Show the second set of serial sections of tumor specimens stained for IFN-γ and IL-10 from two patients shown in the upper panel, both IFN-γ (brown) and IL-10 (brown) were stained individually.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_61373313ce83518614b8fc63af2cb6db |
| identifier_str_mv | 10.1158/1078-0432.30705749 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30705749 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate CancerUlka N. Vaishampayan (15051039)Archana Thakur (15051042)Wei Chen (15051045)Abhinav Deol (15051048)Meera Patel (15051051)Kimberlee Dobson (15051054)Brenda Dickow (15051057)Dana Schalk (15051060)Amy Schienschang (15051063)Sarah Whitaker (15051066)Amanda Polend (15051069)Joseph A. Fontana (411960)Elisabeth I. Heath (15024674)Lawrence G. Lum (15051072)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsGenitourinary CancersProstate cancerImmunotherapyCellular immunotherapy<p>A-C. FFPE sections of PC were stained by multiplex staining panel for CD4, CD8, FoxP3 (T regulatory cells), CD19 (B cells), CD68 (macrophages). Stained sections were imaged on the Hamamatsu slide scanner NanoZoomer S360 and images were viewed on the NDP viewer software. Analysis of images were performed on online Visiopharm software. Using the low power image, high-powered Fields (HPFs) were selected from specific tumor regions. Data shows the distribution of CD4+ (teal), CD8+ (purple), FoxP3 (brown), CD19+ (green) and CD68+ (yellow) cells on two representative whole scanned slide images (KCI 04 and KCI 11) are shown. Top panel shows whole scanned tumor sections, inset 1 and 2 are shown below at high magnification (40x). B and C) Show the second set of serial sections of tumor specimens stained for IFN-γ and IL-10 from two patients shown in the upper panel, both IFN-γ (brown) and IL-10 (brown) were stained individually.</p>2025-11-25T12:41:18ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30705749https://figshare.com/articles/figure/Supplementary_Figure_S3_from_Phase_II_Trial_of_Pembrolizumab_and_Anti-CD3_x_Anti-HER2_Bispecific_Antibody-Armed_Activated_T_Cells_in_Metastatic_Castration-Resistant_Prostate_Cancer/30705749CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307057492025-11-25T12:41:18Z |
| spellingShingle | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer Ulka N. Vaishampayan (15051039) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |
| status_str | publishedVersion |
| title | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_fullStr | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_full_unstemmed | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_short | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| title_sort | Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer |
| topic | Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Prostate cancer Immunotherapy Cellular immunotherapy |